Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?

Area of Science:

• Cardiology
• Genetics
• Sports Medicine

Background:

• Hypertrophic cardiomyopathy (HCM) is a primary cause of sudden cardiac death (SCD) in young populations, notably athletes.
• Effective risk stratification is essential for preventing SCD in individuals with HCM.

Purpose of the Study:

• To emphasize the critical role of noninvasive diagnostic testing in assessing SCD risk in hypertrophic cardiomyopathy patients.
• To highlight key indicators and advanced imaging techniques for identifying individuals at high risk of SCD.

Main Methods:

• Review of noninvasive diagnostic tools including electrocardiography (ECQ/EKG) and cardiac magnetic resonance imaging (CMR).
• Analysis of specific ECG findings like fragmented QRS and T wave inversion.
• Evaluation of CMR capabilities for assessing left ventricular hypertrophy, wall thickness, cardiac mass, and myocardial fibrosis using late gadolinium enhancement (LGE).
• Consideration of genetic testing in HCM risk assessment.

Main Results:

• Extreme left ventricular hypertrophy and documented ventricular arrhythmias are associated with increased SCD risk.
• Fragmented QRS and T wave inversion in multiple leads are more prevalent in high-risk patients.
• CMR provides detailed anatomical and functional information, with LGE identifying myocardial fibrosis, a significant risk marker.
• Genetic testing is recommended, particularly for those with a family history of HCM or SCD.

Conclusions:

• Noninvasive diagnostic testing, including advanced imaging like CMR, is vital for comprehensive risk stratification in HCM.
• Identifying specific ECG abnormalities and myocardial fibrosis aids in predicting SCD risk.
• Genetic evaluation should be considered for all HCM patients to inform risk assessment and family screening.